WeightWatchers Clinic Reviews Liraglutide
Carried in the formulary and used where the weekly agents are unsuitable, but not positioned as a cost-motivated first trial.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “Adjunct” means here
Available and used, but not the centre of the protocol — typically alongside or after another agent.
The pairing
How WeightWatchers Clinic handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Adjunct
- Gating
- Clinician judgment.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- Yes
- Titration protocol
- Clinician-led with monthly check-ins during titration
- Off-ramp
- Transition into the legacy behavioral workshop program at reduced cost
- Care team
- Nurse practitioners, Physicians, Registered dietitians, Workshop coaches
Ask WeightWatchers Clinic this
Is liraglutide ever used as a deliberate lower-cost trial before the weekly agents, and what share of starts does it represent?
Watch out
Verify that the clinical arm and workshop arm actually share data. In practice these have often run as separate systems.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Teladoc Health Navigation & orchestration | Adjunct | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Calibrate Full-service clinical | Adjunct | 7.2 | $65–$110 |
| Transcarent Navigation & orchestration | Orchestrated | 7.1 | $12–$32 |
Same vendor
WeightWatchers Clinic across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
First-line, with clinician-led monthly check-ins during titration. The distinguishing asset is the maintenance off-ramp into the legacy workshop programme once a member tapers.
Offered first-line alongside semaglutide. The behavioral maintenance infrastructure matters more here, since tirzepatide's larger reductions make the post-taper regain risk correspondingly larger.
Used for members with glycemic indications rather than as a required rung ahead of incretin therapy.